0.71
+2.50%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About InspireMD
From its filings with the US Securities and Exchange Commission
InspireMD is based in Miami, Florida and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker NSPR. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $9.0m and a net loss of $48.8m. At that date it held total assets of $69.4m and shareholders' equity of $55.2m.
Administration (“FDA”) on June 23, 2025, and is marketed exclusively in the United States through our direct salesforce.
12-month, the ISR rate (by Core Lab) is lower than those reported in the literature of first-generation stents (Naylor R, et al.
EPS has high conformability combined with an almost equivalent outward radial force at expansion diameters ranging from 5.5 to 9.0 mm.
Procedure, the CGuard arm was observed to have a 57% reduction in new cerebral lesion average volume per patient (171 mm3 vs.
Quoted from its 10-K, filed 18 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 12 Apr 2013
- Employees
- 127
- Website
- inspiremd.com ↗
- Head office
- 6303 WATERFORD DISTRICT DRIVE, MIAMI, FL, 33126
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Paul StukaIndependent Chairman of the Board$281,981
- Mr. Marvin SlosmanPresident, Chief Executive Officer, Director, since 2020$3.3m
- Mr. Michael LawlessChief Financial Officer
- Mr. Andrea TommasoliChief Operating Officer$359,269
- Mr. Pete LigottiExecutive Vice President, General Manager, U.S.
- Mr. Patrick VertaExecutive Vice President -Clinical and Medical Affairs
- Mr. Shane GleasonVice President - Global Marketing, General Manager, North America$1.5m
- Mr. Michael BermanIndependent Director$182,987
- Mr. Raymond CohenIndependent Director
- Mr. Danny DearenIndependent Director
- Dr. Gary RoubinIndependent Director$167,987
- Mr. Scott WardIndependent Director$169,240
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company focuses on MicroNet stent platform technology for vascular and coronary disease treatment
- Offers CGuard EPS combining MicroNet with a self-expandable nitinol stent for carotid artery applications
- Has MGuard Prime EPS marketed in the European Union for coronary disease treatment
Weaknesses
- Company is a medical device firm with limited public financial data available
- No specific mention of revenue or market share in the provided information
- Relies on a single product platform (MicroNet) for multiple applications
Opportunities
- Development of neurovascular flow diverter (NGuard) for endovascular device market
- Potential expansion of MGuard Prime EPS into new geographic markets beyond EU
- Growth in demand for embolic protection systems in stenting procedures
Threats
- Dependence on MicroNet technology may limit diversification
- Competition in the medical device sector could impact market share
- Regulatory challenges may affect commercialization of new products
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.